NAC (N-Acetylcysteine)
N-acetylcysteine (NAC) is a cysteine derivative and FDA-approved mucolytic and acetaminophen antidote that is the most widely studied precursor to glutathione, the cell's primary intracellular antioxidant and detoxification substrate; by replenishing intracellular cysteine, the rate-limiting amino acid for glutathione biosynthesis, NAC supports GPX-mediated hydroperoxide reduction, protects against ferroptotic cell death, and reduces oxidative stress in a diverse range of conditions from neurodegenerative disease to hemoglobin disorders.
Key Takeaways
- •NAC is the primary oral glutathione precursor because it provides cysteine, the rate-limiting amino acid for glutathione biosynthesis, in a form that is stable and orally bioavailable; direct oral glutathione supplementation is largely degraded in the gut, making NAC the preferred route for raising intracellular glutathione levels.
- •GPX4 (phospholipid hydroperoxide glutathione peroxidase), the enzyme that directly prevents ferroptosis by reducing lipid hydroperoxides in cell membranes, is entirely dependent on glutathione as its reductant; NAC supports GPX4 activity by ensuring adequate glutathione substrate availability, making it a direct ferroptosis inhibitor upstream of GPX4.
- •The neuroprotective rationale for NAC in ALS and FUS/TDP-43 proteinopathies rests on the observation that cytoplasmic oxidative stress is a primary trigger for the pathological relocalization of RNA-binding proteins into stress granules; NAC-driven glutathione elevation reduces this oxidative trigger and may delay or reduce FUS and TDP-43 mislocalization.
- •In G6PD deficiency, NAC can provide glutathione precursors to support cellular antioxidant defense, but its effectiveness is fundamentally limited by the lack of NADPH needed to recycle oxidized glutathione (GSSG) back to reduced glutathione (GSH); the benefit is therefore partial and dependent on residual NADPH from alternative sources.
- •SOD1 mutations in familial ALS impair the primary superoxide dismutation defense, generating sustained superoxide-driven oxidative stress in motor neurons; NAC glutathione elevation provides a secondary antioxidant defense through the GPX pathway that partially compensates for impaired SOD1 function.
- •NAC is FDA-approved and has decades of clinical use as an acetaminophen antidote (intravenous administration) and as a mucolytic for chronic obstructive pulmonary disease (oral and inhaled); this extensive clinical use has established a well-defined safety profile at oral doses up to 1,800 mg per day.
- •In PRKN (parkin) deficiency, where impaired mitophagy allows dysfunctional mitochondria to accumulate and generate elevated reactive oxygen species, NAC provides a glutathione buffer against the resulting oxidative stress in dopaminergic neurons, representing a supportive rather than disease-modifying intervention.
Basic Information
- Name
- NAC (N-Acetylcysteine)
- Also Known As
- NACN-acetyl-L-cysteineN-acetylcysteineMucomystFluimucilacetylcysteine
- Category
- Glutathione precursor / mucolytic / antioxidant
- Bioavailability
- Oral bioavailability of NAC is approximately 4 to 10 percent due to extensive first-pass metabolism in the gut and liver, where it is rapidly deacetylated to cysteine, incorporated into glutathione, or converted to other sulfur-containing metabolites. Despite low plasma NAC levels, tissue glutathione elevation is the relevant pharmacodynamic endpoint and occurs reliably after oral dosing. Peak plasma cysteine elevation occurs approximately 1 hour after oral NAC. Effervescent and extended-release formulations may improve absorption. Intravenous NAC bypasses first-pass metabolism and is used for acetaminophen poisoning and ICU applications.
- Half-Life
- Plasma half-life of NAC is approximately 2 to 6 hours; cysteine (the primary active metabolite) has a similar plasma half-life. Glutathione elevation in cells persists longer than the NAC plasma half-life because glutathione itself is stable intracellularly. Twice daily dosing is used in most clinical trials to maintain elevated tissue glutathione throughout the day.
Primary Mechanisms
Cysteine provision for glutathione biosynthesis via gamma-glutamylcysteine synthetase and glutathione synthetase
Direct thiol antioxidant activity through the free sulfhydryl group of NAC and cysteine
GPX1 and GPX4 substrate replenishment supporting hydroperoxide and lipid hydroperoxide reduction
Reduction of disulfide bonds in mucus glycoproteins, improving mucociliary clearance
Electrophile scavenging and detoxification through thiol conjugation
NAPQI (acetaminophen toxic metabolite) neutralization through direct thiol conjugation
Quick Safety Summary
Oral: 600 to 1,800 mg per day in most clinical trials (typically 600 mg two to three times per day). Intravenous: 150 mg/kg loading dose followed by maintenance infusion for acetaminophen toxicity. Doses up to 3,000 mg per day have been used in some trials. Most studies are 3 to 12 months in duration; long-term safety data for continuous use beyond 12 months is limited but the clinical experience from COPD and cystic fibrosis management is reassuring.
Asthma: inhaled NAC can cause bronchospasm due to its irritant properties; inhalation form requires bronchodilator pretreatment; oral supplementation is generally well-tolerated in asthma, Active peptic ulcer disease: NAC reduces the viscosity of gastric mucus and may transiently reduce the mucus barrier in the stomach; use with caution in active ulcer disease, Concurrent nitroglycerin use: NAC potentiates the hypotensive and vasodilatory effects of nitroglycerin, increasing the risk of severe hypotension; this interaction requires medical supervision
Overview
N-acetylcysteine (NAC) was developed in the 1960s as a mucolytic agent to reduce the viscosity of respiratory mucus in chronic obstructive pulmonary disease and cystic fibrosis, exploiting the ability of its free thiol group to cleave disulfide bonds within mucus glycoproteins. Its value as a glutathione precursor and antioxidant was recognized subsequently, and today NAC is one of the most versatile and well-characterized compounds in clinical pharmacology, with FDA-approved indications as an acetaminophen antidote and mucolytic alongside a large body of evidence for its use in respiratory, neurological, and metabolic conditions. The central pharmacological mechanism is straightforward: after absorption and deacetylation to cysteine, NAC raises intracellular cysteine levels, overcoming the rate-limiting step in de novo glutathione biosynthesis. Glutathione is the cell's primary intracellular antioxidant buffer, present at millimolar concentrations in most cells, and it is the essential reductant for the glutathione peroxidase (GPX) family of enzymes that reduce hydrogen peroxide, organic hydroperoxides, and lipid hydroperoxides in a reaction that is tightly coupled to NADPH availability through glutathione reductase.
The ferroptosis-preventing activity of NAC has gained considerable mechanistic and clinical relevance in recent years. Ferroptosis is a regulated form of iron-dependent cell death driven by the unchecked accumulation of lipid hydroperoxides in cell membranes, a process catalyzed by iron-dependent lipid peroxidation reactions. The primary cellular defense against ferroptosis is GPX4 (phospholipid hydroperoxide glutathione peroxidase), which reduces lipid hydroperoxides embedded in cellular membranes using glutathione as the electron donor. When cellular glutathione is depleted -- by oxidative stress, cystine transport inhibition (system Xc- blockade), or GPX4 inactivation -- lipid hydroperoxides accumulate and ferroptosis ensues. NAC prevents ferroptosis by ensuring adequate glutathione substrate availability for GPX4, and this mechanism is relevant in multiple pathological contexts: in neurodegeneration where iron accumulates in vulnerable neurons, in ischemia-reperfusion injury, and in the context of GPX4 variants that reduce enzyme efficiency, where glutathione substrate availability may be the rate-limiting factor for ferroptosis prevention.
The role of NAC in neurodegeneration, particularly in ALS and related RNA-binding protein proteinopathies, connects to the biology of oxidative stress-triggered protein mislocalization. FUS (fused in sarcoma), TDP-43 (TARDBP), and other RNA-binding proteins that are mutated or misregulated in ALS and frontotemporal dementia normally reside in the nucleus. Under conditions of cellular stress, including oxidative stress, these proteins can mislocalize to cytoplasmic stress granules. In cells expressing ALS-associated mutant forms, this stress-induced mislocalization is exaggerated and can lead to stable cytoplasmic inclusions rather than reversible stress granules. Oxidative stress is a particularly potent trigger for this mislocalization in part because cysteine residues in these RNA-binding proteins are susceptible to oxidative modification, which alters their solubility and nuclear localization signal function. NAC, by reducing the cytoplasmic oxidative environment through glutathione elevation, may reduce the frequency and severity of oxidative stress-triggered protein mislocalization events, providing a supportive mechanism relevant to ALS disease modification.
The PARK7 (DJ-1) and PRKN (parkin) connections illustrate how NAC interacts with the Parkinson disease biology of dopaminergic neuron vulnerability. PARK7/DJ-1 is itself a redox-sensitive chaperone and antioxidant protein that is directly oxidized by hydrogen peroxide, and its oxidation is a marker of cellular oxidative stress. When PARK7 function is insufficient (due to loss-of-function mutations) or overwhelmed (due to high oxidative burden), dopaminergic neurons lose a critical protective mechanism. PRKN encodes parkin, the E3 ubiquitin ligase that coordinates PINK1-Parkin mitophagy of depolarized mitochondria; parkin loss allows dysfunctional mitochondria to accumulate and generate elevated ROS, further stressing dopaminergic neurons. NAC supports both of these dopaminergic protection pathways by providing the cysteine building blocks that maintain the glutathione system, reducing the oxidative burden that PARK7 must buffer and that would otherwise promote alpha-synuclein aggregation and neuronal loss in the substantia nigra.
Gene Interactions
Key Gene Targets
FTH1
NAC is a precursor to glutathione, the primary co-substrate for GPX4, which works alongside FTH1 (ferritin heavy chain) to prevent ferroptosis; while FTH1 sequesters iron to prevent Fenton-driven lipid peroxidation, GPX4-mediated glutathione-dependent reduction of lipid hydroperoxides is the direct anti-ferroptotic effector, and NAC supports GPX4 function by maintaining adequate glutathione substrate.
GPX1
NAC is a direct precursor to glutathione (GSH), the essential reductant and substrate for GPX1-mediated detoxification of hydrogen peroxide and organic hydroperoxides; by increasing intracellular cysteine availability, NAC raises cellular GSH levels and thereby increases the substrate pool available for GPX1 catalysis, improving the cell's capacity to neutralize H2O2 and organic peroxides.
GPX4
NAC provides cysteine as a glutathione biosynthesis precursor, ensuring adequate supply of the glutathione reductant that GPX4 requires to reduce phospholipid hydroperoxides and prevent ferroptosis; glutathione depletion is a proximal cause of GPX4 inactivation and ferroptotic cell death, and NAC prevents this depletion, maintaining GPX4's anti-ferroptotic activity.
PARK7
NAC provides the cysteine building blocks needed to maintain the glutathione system, which works in close partnership with PARK7 (DJ-1) to protect dopaminergic neurons from oxidative damage; while PARK7 directly buffers oxidative stress through its own cysteine-dependent redox activity, NAC-supported glutathione elevation provides complementary protection when PARK7 is insufficient or lost.
Safety & Dosing
Contraindications
Asthma: inhaled NAC can cause bronchospasm due to its irritant properties; inhalation form requires bronchodilator pretreatment; oral supplementation is generally well-tolerated in asthma
Active peptic ulcer disease: NAC reduces the viscosity of gastric mucus and may transiently reduce the mucus barrier in the stomach; use with caution in active ulcer disease
Concurrent nitroglycerin use: NAC potentiates the hypotensive and vasodilatory effects of nitroglycerin, increasing the risk of severe hypotension; this interaction requires medical supervision
Drug Interactions
Nitroglycerin: potentiates vasodilatory and hypotensive effects; the NAC-nitroglycerin combination produces synergistic reductions in blood pressure and may cause severe hypotension; avoid unless medically supervised
Activated charcoal: charcoal binds NAC in the gut and reduces its absorption; separate by at least 2 hours
Carbamazepine: some evidence that NAC may reduce carbamazepine efficacy through glutathione-mediated oxidative metabolism effects; monitor seizure control when combining
Antibiotics: NAC improves mucociliary clearance and reduces biofilm formation in bacterial respiratory infections, potentially enhancing antibiotic penetration; this interaction is generally beneficial in respiratory infection contexts
Common Side Effects
GI discomfort (nausea, vomiting, diarrhea) is the most common side effect, occurring in 10 to 15 percent of users at standard doses; taking with food and using effervescent forms reduces GI side effects
Sulfurous odor of breath and urine from cysteine and hydrogen sulfide metabolites; cosmetically unpleasant but pharmacologically insignificant
Studied Doses
Oral: 600 to 1,800 mg per day in most clinical trials (typically 600 mg two to three times per day). Intravenous: 150 mg/kg loading dose followed by maintenance infusion for acetaminophen toxicity. Doses up to 3,000 mg per day have been used in some trials. Most studies are 3 to 12 months in duration; long-term safety data for continuous use beyond 12 months is limited but the clinical experience from COPD and cystic fibrosis management is reassuring.
Mechanism of Action
After oral absorption, NAC is deacetylated by aminoacylase in the gut mucosa, liver, and kidney to produce cysteine. Intracellular cysteine is then condensed with glutamate by gamma-glutamylcysteine synthetase (the rate-limiting enzyme of glutathione biosynthesis), producing gamma-glutamylcysteine, which is then condensed with glycine by glutathione synthetase to form glutathione (GSH). The elevated GSH serves as the electron donor for the GPX family of enzymes: GPX1 reduces hydrogen peroxide and small organic hydroperoxides; GPX4 reduces phospholipid hydroperoxides embedded in cellular membranes, directly preventing ferroptosis. Each catalytic cycle of GPX oxidizes two GSH molecules to GSSG (glutathione disulfide), which is subsequently reduced back to GSH by glutathione reductase at the cost of NADPH. This recycling means that the net glutathione consumption is dependent on the rate of NADPH availability through the pentose phosphate pathway, explaining why conditions of NADPH deficiency (G6PD deficiency) limit the effectiveness of glutathione replenishment by NAC.
NAC also has direct antioxidant activity independent of glutathione synthesis. The free thiol group of the cysteine moiety can directly donate a hydrogen atom to quench hydroxyl radicals and hypochlorous acid, and can form mixed disulfides with reactive protein thiols, protecting them from irreversible oxidative modification. The thiol can also directly conjugate electrophilic compounds, providing a stoichiometric detoxification capacity. In the mucus-thinning application, NAC directly reduces the intermolecular disulfide bonds between mucin glycoproteins that maintain the gel-like viscoelastic structure of respiratory and GI mucus, reducing viscosity and improving clearance. This mucolytic mechanism is entirely separate from the antioxidant and glutathione-precursor mechanisms and explains NAC’s clinical efficacy in COPD exacerbation prevention even at doses where systemic glutathione elevation may be modest.
Clinical Evidence
The clinical evidence for NAC is strongest in its approved indications: acetaminophen toxicity (intravenous NAC reduces mortality from fulminant hepatic failure when administered within 10 hours of overdose) and COPD exacerbation prevention (oral NAC at 600 to 1,200 mg per day reduces exacerbation frequency in meta-analyses of multiple randomized trials). Beyond these established indications, the evidence base in neurological conditions is developing. A randomized trial of intravenous NAC in mild cognitive impairment showed improvements in global cognition and reduced oxidative stress biomarkers. Pilot studies in ALS patients have demonstrated safety and glutathione elevation. Studies in sickle cell disease have shown reductions in F2-isoprostanes (lipid peroxidation markers) and endothelial activation markers, supporting the antioxidant rationale in hemoglobin disorders. In Parkinson disease contexts, a systematic review of NAC trials found improvements in dopamine system function as measured by dopamine transporter SPECT imaging, providing indirect support for the neuroprotective mechanism. The overall picture is of a compound with proven pharmacological activity, established safety, and a mechanistic profile that supports applications across multiple conditions defined by oxidative stress and glutathione depletion.
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
Comprehensive clinical review of NAC as the standard of care for acetaminophen overdose, establishing the mechanism (glutathione precursor repleting the hepatic glutathione depleted by NAPQI, the toxic acetaminophen metabolite) and the clinical protocols that have reduced acetaminophen-related liver failure mortality; this clinical approval validates the fundamental pharmacology of NAC as a glutathione precursor in humans.
Mechanistic study establishing the molecular basis for NAC as a ferroptosis inhibitor, demonstrating that NAC maintains cellular glutathione levels and thereby supports GPX4-mediated lipid hydroperoxide reduction; the study confirmed that NAC protects against ferroptotic cell death in multiple cell types and identified the GPX4-glutathione axis as the mechanistic target.
Randomized double-blind trial of oral NAC (50 mg/kg per day) in 111 ALS patients over 12 months showing a non-significant trend toward slower decline with a favorable safety profile; established the tolerability and safety basis for NAC in ALS and contributed to the rationale for antioxidant approaches in SOD1-mediated and broader ALS pathology.
Glutathione precursor N-acetylcysteine inhibits ferroptosis by elevating GPX4 activity and GSH level
In vivo and in vitro study demonstrating that NAC inhibits ferroptosis in multiple cell types and organ models by elevating intracellular glutathione and supporting GPX4 enzyme activity, providing evidence that NAC anti-ferroptotic protection is mediated primarily through the GSH-GPX4 axis rather than direct radical scavenging.
Systematic review and meta-analysis of NAC clinical trials in Parkinson disease showing improvements in dopamine system function and reduced oxidative stress biomarkers, with the strongest evidence from combination IV plus oral NAC protocols; provided the rationale for ongoing investigation of NAC in PARK7- and PRKN-related Parkinson disease contexts.